

In-Hospital Electrocardiographic (ECG) Telemetry Monitoring for Acute Heart Failure: A Rapid Review

M Nikitovic

December 2012

Suggested Citation

This report should be cited as follows:

Nikitovic M. In-hospital electrocardiographic (ECG) telemetry monitoring for acute heart failure: a rapid review. Toronto, ON: Health Quality Ontario; 2012 Dec. 16 p. Available from: http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations/rapid-reviews.

Conflict of Interest Statement

All reports prepared by the Division of Evidence Development and Standards at Health Quality Ontario are impartial. There are no competing interests or conflicts of interest to declare.

Rapid Review Methodology

Clinical questions are developed by the Division of Evidence Development and Standards at Health Quality Ontario in consultation with experts, end-users, and/or applicants in the topic area. A systematic literature search is then conducted to identify relevant systematic reviews, health technology assessments, and meta-analyses; if none are located, the search is expanded to include randomized controlled trials (RCTs), and guidelines. Systematic reviews are evaluated using a rating scale developed for this purpose. If the systematic review has evaluated the included primary studies using the GRADE Working Group criteria (http://www.gradeworkinggroup.org/index.htm), the results are reported and the rapid review process is complete. If the systematic review has not evaluated the primary studies using GRADE, the primary studies included in the systematic review are retrieved and a maximum of two outcomes are graded. If no well-conducted systematic reviews are available, RCTs and/or guidelines are evaluated. Because rapid reviews are completed in very short timeframes, other publication types are not included. All rapid reviews are developed and finalized in consultation with experts.

Disclaimer

This rapid review is the work of the Division of Evidence Development and Standards at Health Quality Ontario, and is developed from analysis, interpretation, and comparison of published scientific research. It also incorporates, when available, Ontario data and information provided by experts. As this is a rapid review, it may not reflect all the available scientific research and is not intended as an exhaustive analysis. Health Quality Ontario assumes no responsibility for omissions or incomplete analysis resulting from its rapid reviews. In addition, it is possible that other relevant scientific findings may have been reported since completion of the review. This report is current to the date of the literature search specified in the Research Methods section, as appropriate. This rapid review may be superseded by an updated publication on the same topic. Please check the Health Quality Ontario website for a list of all publications: http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations.

About Health Quality Ontario

Health Quality Ontario is an arms-length agency of the Ontario government. It is a partner and leader in transforming Ontario's health care system so that it can deliver a better experience of care, better outcomes for Ontarians, and better value for money.

Health Quality Ontario strives to promote health care that is supported by the best available scientific evidence. Health Quality Ontario works with clinical experts, scientific collaborators, and field evaluation partners to develop and publish research that evaluates the effectiveness and cost-effectiveness of health technologies and services in Ontario.

Based on the research conducted by Health Quality Ontario and its partners, the Ontario Health Technology Advisory Committee (OHTAC)—a standing advisory subcommittee of the Health Quality Ontario Board—makes recommendations about the uptake, diffusion, distribution, or removal of health interventions to Ontario's Ministry of Health and Long-Term Care, clinicians, health system leaders, and policy makers.

Rapid reviews, evidence-based analyses and their corresponding OHTAC recommendations, and other associated reports are published on the Health Quality Ontario website. Visit http://www.hqontario.ca for more information.

About Health Quality Ontario Publications

To conduct its rapid reviews, Health Quality Ontario and/or its research partners reviews the available scientific literature, making every effort to consider all relevant national and international research; collaborates with partners across relevant government branches; consults with clinical and other external experts and developers of new health technologies; and solicits any necessary supplemental information.

In addition, Health Quality Ontario collects and analyzes information about how a health intervention fits within current practice and existing treatment alternatives. Details about the diffusion of the intervention into current health care practices in Ontario can add an important dimension to the review. Information concerning the health benefits, economic and human resources, and ethical, regulatory, social, and legal issues relating to the intervention may be included to assist in making timely and relevant decisions to optimize patient outcomes.

Permission Requests

All inquiries regarding permission to reproduce any content in Health Quality Ontario reports should be directed to: EvidenceInfo@hqontario.ca.

How to Obtain Rapid Reviews From Health Quality Ontario

All rapid reviews are freely available in PDF format at the following URL: http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations/rapid-reviews.

Table of Contents

Table of Contents	4
List of Abbreviations	5
Background	6
Objective of Analysis	
Clinical Need and Target Population	6
Technology	
Rapid Review	7
Research Question	7
Research Methods	7
Literature Search	<i>7</i>
Inclusion Criteria	7
Exclusion Criteria	7
Outcome of Interest	7
Expert Panel	7
Results of Literature Search	8
Conclusions	10
Acknowledgements	11
Appendices	
Appendix 1: Literature Search Strategies	
References	

List of Abbreviations

AHA American Heart Association

CCS Canadian Cardiovascular Society

ECG Electrocardiography

ESC European Society of Cardiology

HF Heart failure

HFSA Heart Failure Society of America

RCT Randomized controlled trial

Background

As legislated in Ontario's *Excellent Care for All Act*, Health Quality Ontario's mandate includes the provision of objective, evidence-informed advice about health care funding mechanisms, incentives, and opportunities to improve quality and efficiency in the health care system. As part of its Quality-Based Funding (QBF) initiative, Health Quality Ontario works with multidisciplinary expert panels (composed of leading clinicians, scientists, and administrators) to develop evidence-based practice recommendations and define episodes of care for selected disease areas or procedures. Health Quality Ontario's recommendations are intended to inform the Ministry of Health and Long-Term Care's Health System Funding Strategy.

For more information on Health Quality Ontario's Quality-Based Funding initiative, visit www.hqontario.ca.

Objective of Analysis

The objective of this analysis was to determine the effectiveness of electrocardiography (ECG) telemetry monitoring among patients hospitalized for acute heart failure (HF).

Clinical Need and Target Population

Significant variations in cardiac rhythm can occur either as a precursor to, or as a result of, acute HF. In particular, acute HF is a major risk factor for the development of clinically significant ventricular and atrial arrhythmias, which may result in morbidity or cardiac death. (1;2) Additionally, some therapies for acute HF have been shown to exhibit proarrhythmic properties. (3) Early detection of significant variations in cardiac rate and rhythm may facilitate acute HF patient management through early and appropriate therapeutic intervention.

Technology

Inpatient ECG telemetry monitoring is a noninvasive method that allows for continuous, real-time detection of significant variations in a patient's cardiac rhythm and electrical activity. (4) Telemetry can detect complex dysrhythmias, myocardial ischemia, and prolonged QT-intervals. (4) During inpatient ECG telemetry monitoring, electrocardiographic signals are acquired from electrodes that are attached to the patient's chest and lead wires connected to a telemetry device. (5) The ECG signal is transmitted via radio frequency to a central monitoring station, where health care professionals can continuously monitor patient activity and are alerted to rhythm disturbances. Signals are also received or hard-wired to the patient's bedside monitor display. (5) The number of hospital beds with telemetry monitoring is often limited; the use of this resource among acute HF patients should be appropriately assessed.

Rapid Review

Research Question

What is the effectiveness of ECG telemetry monitoring among patients hospitalized with acute HF in comparison to standard care?

Research Methods

Literature Search

A literature search was performed on October 17, 2012, using OVID MEDLINE, OVID MEDLINE In-Process and Other Non-Indexed Citations, OVID EMBASE, the Wiley Cochrane Library, and the Centre for Reviews and Dissemination database, for studies published from January 1, 2002, until October 17, 2012. Abstracts were reviewed by a single reviewer and, for those studies meeting the eligibility criteria, full-text articles were obtained. Reference lists were also examined for any additional relevant studies not identified through the search.

Inclusion Criteria

- English language full-reports
- published between January 1, 2002, and October 17, 2012
- systematic reviews, meta-analyses, health technology assessments, clinical practice guidelines, or randomized controlled trials (RCTs)
- adult acute HF population
- studies evaluating in-hospital ECG telemetry monitoring

Exclusion Criteria

- observational studies, case reports, editorials
- standard 12-lead ECG or ambulatory ECG monitoring (e.g., Holter monitoring)

Outcome of Interest

mortality

Expert Panel

In August 2012, an Expert Advisory Panel on Episode of Care for Congestive Heart Failure was struck. Members of the panel included physicians, personnel from the Ministry of Health and Long-Term Care, and representation from the community laboratories.

The role of the Expert Advisory Panel on Episode of Care for Congestive Heart Failure was to contextualize the evidence produced by Health Quality Ontario and provide advice on the components of a high-quality episode of care for HF patients presenting to an acute care hospital. However, the statements, conclusions and views expressed in this report do not necessarily represent the views of Expert Advisory Panel members.

Results of Literature Search

The database search yielded 1,393 citations published between January 1, 2002, and October 17, 2012 (with duplicates removed). Articles were excluded based on information in the title and abstract. The full texts of potentially relevant articles were obtained for further assessment.

No health technology assessments, meta-analyses, systematic reviews or RCTs were identified in the literature search that evaluated ECG telemetry monitoring among an acute HF population.

Four clinical practice guidelines that discussed continuous ECG monitoring for the management of HF in hospital were identified from a hand search of the literature: the 2004 American Heart Association (AHA) Scientific Statement on Practice Standards for Electrocardiographic Monitoring in Hospital Settings; the 2012 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure; the Heart Failure Society of America (HFSA) 2010 Comprehensive Heart Failure Practice Guideline; and the 2007 Canadian Cardiovascular Society (CCS) Consensus Conference Recommendations on Heart Failure. (3;4;6;7) Other guidelines reviewed did not make recommendations regarding real-time ECG telemetry monitoring. Descriptions of the above guidelines and their recommendations related to in-hospital ECG telemetry monitoring or continuous ECG monitoring are provided in Table 1.

Table 1: Summary of Heart Failure Guidelines Related to Continuous ECG Telemetry Monitoring

Guideline	Heart Failure Population	Recommendation	Class/Level of Evidence
AHA, 2004 (4)	Acute HF/pulmonary edema	Continuous monitoring is recommended for all patients until the signs and symptoms of acute HF have resolved and cardiac monitoring reveals no hemodynamically significant arrhythmias for at least 24 hours	Class I ^a Expert opinion
	Subacute HF	In the absence of RCTs, it seems reasonable to perform ECG monitoring in the subacute phase of acute HF while medications, device therapy, or both are being manipulated	Class II ^b Expert opinion
ESC, 2012 (6)	Acute HF with hypotension, hypoperfusion, or shock, and IV infusion of an inotrope or vasopressor	ECG should be monitored continuously, because these agents can cause arrhythmias and myocardial ischemia	NA Expert opinion
HFSA, 2010 (3)	Acute decompensated HF plus IV inotrope administration	Administration of IV inotropes (milrinone or dobutamine) should be accompanied by continuous or frequent blood pressure monitoring and continuous monitoring of cardiac rhythm	C°
CCS, 2007 (7)	Acute HF	Cardiac arrhythmias should be evaluated by a 12-lead ECG and continuous ECG monitoring.	Unclear ^d

Abbreviations: AHA, American Heart Association; CCS, Canadian Cardiovascular Society; ECG, electrocardiograph(y); ESC, European Society of Cardiology; HF, heart failure; HFSA, Heart Failure Society of America; IV, intravenous; NA, not available; RCT, randomized controlled trial.

aClass I: cardiac monitoring is indicated in most, if not all, patients in this group. Includes all patients at significant risk of immediate, life-threatening arrhythmia

^bClass II: cardiac monitoring may be of benefit in some patients, but is not considered essential for all patients. ECG telemetry monitoring was considered helpful in the clinical management of Class II patients, but is not expected to save lives. Cardiac monitoring often takes place in an intermediate care (telemetry) unit.

^cLevel C evidence is based on expert opinion.

^dThe comment suggesting ECG monitoring was not directly assessed.

Evidence for the use of ECG monitoring was based largely on expert opinion for all recommendations.

The AHA scientific statement was the only guideline to directly evaluate practice standards for real-time ECG monitoring performed in hospital settings. (4) Electrocardiography monitoring for cardiac arrhythmias was recommended for all acute HF patients, based on evidence surrounding the contribution of arrhythmias to acute cardiac decompensation, and the risk for atrial and ventricular arrhythmias among this population. Monitoring was also considered valuable for patients on intravenous positive inotropic drugs (as they have significant proarrhythmic properties), and during the administration of nesiritide (to detect sinus tachycardia). Whether ECG monitoring should be used for subacute HF was unclear, but was recommended while medications and devices are being manipulated.

Continuous ECG monitoring was recommended in both the ESC and HFSA guidelines for acute HF patients undergoing administration of intravenous inotropes, based on increased risk of arrhythmias and myocardial ischemia. (3;6)

The CCS recommends identification of the precipitating cause of acute HF, evaluating cardiac arrhythmias with a 12-lead ECG and continuous ECG monitoring. (7) However, it is unclear from this guideline whether continuous monitoring refers to inpatient telemetry monitoring.

Conclusions

- No high-quality evidence was identified that evaluated the effectiveness of ECG telemetry monitoring among patients with acute HF.
- Based on expert opinion, clinical practice guidelines recommend the use of continuous ECG
 monitoring among patients with acute HF. The AHA practice standards for in-hospital ECG
 monitoring and the CCS recommend continuous ECG monitoring among all patients with acute
 HF. The ESC and HFSA guidelines recommend continuous ECG monitoring among acute HF
 patients treated with inotropes, based on the increased risk of arrhythmia and myocardial ischemia
 associated with these agents.

Acknowledgements

Editorial Staff

Jeanne McKane, CPE, ELS(D)

Medical Information Services

Kaitryn Campbell, BA(H), BEd, MLIS Corinne Holubowich, Bed, MLIS Kellee Kaulback, BA(H), MISt

Episode of Care for Congestive Heart Failure Expert Panel

Name	Title	Organization
Dr. David Alter	Senior Scientist	Institute for Clinical Evaluative Sciences Research Program Director and Associate Staff, The Cardiac and Secondary Prevention Program at the Toronto Rehabilitation Institute-UHN
		Associate Professor of Medicine, University of Toronto
Dr. Douglas Lee	Scientist	Institute for Clinical Evaluative Sciences
Dr. Catherine Demers	Associate Professor	Division of Cardiology, Department of Medicine McMaster University
Dr. Susanna Mak	Cardiologist	University of Toronto, Department of Medicine, Division of Cardiology, Mount Sinai Hospital
Dr. Lisa Mielniczuk	Medical Director, Pulmonary Hypertension Clinic	University of Ottawa Heart Institute
Dr. Peter Liu	President, International Society of Cardiomyopathy and Heart Failure of the World Heart Federation Director, National C- CHANGE Program Scientific Director/VP Research, University of Ottawa Heart Institute Professor of Medicine	University of Ottawa Heart Institute
Dr. Robert McKelvie	Professor of Medicine, Cardiologist	McMaster University, Hamilton Health Sciences
Dr. Malcolm Arnold	Professor of Medicine	University of Western Ontario, London Health Sciences Centre
Dr. Stuart Smith	Chief of Cardiovascular Services Director, Heart Failure Program	St. Mary's General Hospital
Dr. Atilio Costa Vitali	Assistant Professor of Medicine Division of Clinical Science	Sudbury Regional Hospital

Dr. Jennifer Everson	Physician Lead	Hamilton Niagara Haldimand Brant Local Health Integration Network
Dr. Lee Donohue	Family Physician	Ottawa
Linda Belford	Nurse Practitioner, Practice Leader PMCC	University Health Network
Jane MacIver	Nurse Practitioner Heart Failure/Heart Transplant	University Health Network
Sharon Yamashita	Clinical Coordinator, Critical Care	Sunnybrook Health Sciences Centre
Claudia Bucci	Clinical Coordinator, Cardiovascular Diseases	Sunnybrook Health Sciences Centre
Andrea Rawn	Evidence Based Care Program Coordinator	Grey Bruce Health Network
Darlene Wilson	Registered Nurse	Heart Function Clinic, Trillium Health Centre
Kari Kostiw	Clinical Coordinator	Health Sciences North
		Ramsey Lake Health Centre
Janet Parr	CHF Patient	
Heather Sherrard	Vice President, Clinical Services	University of Ottawa Heart Institute
Sue Wojdylo	Manager, Case Costing	Lakeridge Health
Jane Chen	Manager of Case Costing	University Health Network
Nancy Hunter	LHIN Liaison & Business Development	Cardiac Care Network of Ontario
Ministry Representatives		
Gary Coleridge	Senior Program Consultant	Ministry of Health and Long-Term Care
Louie Luo	Senior Methodologist	Ministry of Health and Long-Term Care

Appendices

Appendix 1: Literature Search Strategies

Database: Ovid MEDLINE(R) <1946 to October Week 1 2012>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <October 16, 2012>, Embase <1980 to 2012 Week 41> Search Strategy:

#	Searches	Results
1	exp heart failure/	327674
2	(((cardia? or heart) adj (decompensation or failure or incompetence or insufficiency)) or cardiac stand still or ((coronary or myocardial) adj (failure or insufficiency))).ti,ab.	258486
3	or/1-2	417506
4	exp *electrocardiography/	107203
5	(electrocardiogram* or ecg* or ekg* or electrocardiograph*).ti,ab.	213410
6	(telemetry adj2 (unit* or cardiac)).ti,ab.	562
7	or/4-6	260511
8	3 and 7	21725
9	Meta Analysis.pt.	36967
10	Meta Analysis/ use emez	66488
11	Systematic Review/ use emez	53812
12	exp Technology Assessment, Biomedical/ use mesz	8872
13	Biomedical Technology Assessment/ use emez	11399
14	(meta analy* or metaanaly* or pooled analysis or (systematic* adj2 review*) or published studies or published literature or medline or embase or data synthesis or data extraction or cochrane).ti,ab.	293134
15	((health technolog* or biomedical technolog*) adj2 assess*).ti,ab.	3681
16	exp Random Allocation/ use mesz	76138
17	exp Double-Blind Method/ use mesz	117653
18	exp Control Groups/ use mesz	1376
19	exp Placebos/ use mesz	31442
20	Randomized Controlled Trial/ use emez	330814
21	exp Randomization/ use emez	59725
22	exp Random Sample/ use emez	4238
23	Double Blind Procedure/ use emez	111398
24	exp Triple Blind Procedure/ use emez	35
25	exp Control Group/ use emez	38585
26	exp Placebo/ use emez	206599
27	(random* or RCT).ti,ab.	1385590
28	(placebo* or sham*).ti,ab.	448978
29	(control* adj2 clinical trial*).ti,ab.	38400
30	exp Practice Guideline/ use emez	278889
31	exp Professional Standard/ use emez	269259
32	exp Standard of Care/ use mesz	582
33	exp Guideline/ use mesz	23126
34	exp Guidelines as Topic/ use mesz	102415
35	(guideline* or guidance or consensus statement* or standard or standards).ti.	219538
36	(controlled clinical trial or meta analysis or randomized controlled trial).pt.	456548

3	7 or/9-36	2979438
3	8 8 and 37	2607
3	9 limit 38 to english language	2316
4	0 limit 39 to yr="2002 -Current"	1627
4	1 remove duplicates from 40	1275

Cochrane Library

ID	Search	Hits
#1	MeSH descriptor: [Heart Failure] explode all trees	4862
#2	((cardia? or heart) next (decompensation or failure or incompetence or insufficiency)) or cardiac stand still or ((coronary or myocardial) next (failure or insufficiency)):ti,ab,kw (Word variations have been searched)	9326
#3	#1 or #2	9331
#4	MeSH descriptor: [Electrocardiography] explode all trees	7189
#5	(electrocardiogram* or ecg* or ekg* or electrocardiograph*):ti (Word variations have been searched)	994
#6	(telemetry adj2 (unit* or cardiac)):ti,ab,kw (Word variations have been searched)	0
#7	#4 or #5	7480
#8	#3 and #7 from 2002 to 2012	294

CRD

Line	Search	Hits
1	MeSH DESCRIPTOR heart failure EXPLODE ALL TREES	510
2	(((cardia? or heart) next (decompensation or failure or incompetence or insufficiency)) or cardiac stand still or	312
2	((coronary or myocardial) next (failure or insufficiency))):TI	312
3	#1 OR #2	548
4	MeSH DESCRIPTOR electrocardiography EXPLODE ALL TREES	224
5	((electrocardiogram* or ecg* or ekg* or electrocardiograph*)):TI	50
6	(telemetry adj2 (unit* or cardiac)):TI	0
7	#4 OR #5	232
8	#3 AND #7	14
9	(#8):TI FROM 2002 TO 2012	14

References

- (1) Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009 May 12;119(18):2516-25.
- (2) Cleland JG, Chattopadhyay S, Khand A, Houghton T, Kaye GC. Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev. 2002 Jul;7(3):229-42.
- (3) Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010 Jun;16(6):e1-194.
- (4) Drew BJ, Califf RM, Funk M, Kaufman ES, Krucoff MW, Laks MM, et al. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. Circulation. 2004 Oct 26;110(17):2721-46.
- (5) Turakhia MP, Estes NA, III, Drew BJ, Granger CB, Wang PJ, Knight BP, et al. Latency of ECG displays of hospital telemetry systems: a science advisory from the American Heart Association. Circulation. 2012 Sep 25;126(13):1665-9.
- (6) McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012 Aug;14(8):803-69.
- (7) Arnold JM, Howlett JG, Dorian P, Ducharme A, Giannetti N, Haddad H, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol. 2007 Jan;23(1):21-45.

Health Quality Ontario
130 Bloor Street West, 10th Floor
Toronto, Ontario
M5S 1N5
Tel: 416-323-6868

Toll Free: 1-866-623-6868 Fax: 416-323-9261

Email: <u>EvidenceInfo@hqontario.ca</u> www.hqontario.ca

© Queen's Printer for Ontario, 2012